Responses to central Na(+) and ouabain are attenuated in transgenic rats deficient in brain angiotensinogen.
Studies with angiotensin (Ang) II type 1 receptor blockers suggest that the brain renin-angiotensin system contributes to sodium-induced sympathoexcitation and hypertension. To provide more specific evidence for the involvement of Ang II, locally produced in the brain, transgenic rats were used, which express an antisense RNA against angiotensinogen mRNA specifically in the brain, reducing angiotensinogen levels in the brain by >90%. In freely moving transgenic rats and Sprague-Dawley rats as control animals, blood pressure and heart rate responses to intracerebroventricular infusion (3.8 microL/min for 10 minutes) of artificial cerebrospinal fluid and Na(+)-rich artificial cerebrospinal fluid (containing 0.2, 0.3, and 0.45 mol/L Na(+)) as well as intracerebroventricular injection of ouabain (0.3 and 0.6 microgram/2 microL) were assessed. Central infusion of Na(+)-rich artificial cerebrospinal fluid increased blood pressure and heart rate in a dose-related manner. However, the peak increases by each dose of Na(+) were attenuated by 50% to 70% in the transgenic versus Sprague-Dawley rats. Increases in blood pressure and heart rate in response to ouabain at both doses were attenuated by 55% to 70% in the transgenic versus Sprague-Dawley rats. In the hypothalamus, Ang I level was markedly lower (31+/-9 versus 76+/-13 pg/g, P<0.05) and Ang II level tended to be lower in the transgenic versus Sprague-Dawley rats. These results indicate that the production of angiotensins in the brain is decreased in transgenic rats. The attenuated sympathoexcitatory and pressor responses to ouabain and Na(+)-rich artificial cerebrospinal fluid in transgenic rats support the concept that the local brain renin-angiotensin system, that is, locally produced Ang II, plays an important role in the sympathoexcitatory effects of ouabain and sodium.
University of Ottawa Heart Institute, Ottawa, Ontario, Canada.
B S
BS
Huang
D
D
Ganten
F H
FH
Leenen
D000803:Angiotensin I / Q000378:metabolism; D000804:Angiotensin II / Q000378:metabolism; D000808:Angiotensinogen / Q000172:deficiency*; D000818:Animals; D030801:Animals, Genetically Modified; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000378:metabolism*; D002555:Cerebrospinal Fluid / Q000737:chemistry; D006339:Heart Rate / Q000187:drug effects; D007276:Injections, Intraventricular; D008297:Male; D010042:Ouabain / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012084:Renin-Angiotensin System; D012964:Sodium / Q000494:pharmacology*
D000808:Angiotensinogen; D000804:Angiotensin II; D010042:Ouabain; D000803:Angiotensin I; D012964:Sodium